Mazouni C.,IGR |
Mazouni C.,Laboratory Of Transfert Biologique Oncologique |
Mazouni C.,Institute Gustave Roussy |
Romain S.,Laboratory Of Transfert Biologique Oncologique |
And 3 more authors.
Cancer Biology and Therapy | Year: 2011
Background: Tumor-related proteases such as urokinase-type plasminogen (uPA ), plasminogen activator inhibitor (PA I-1) and cathepsin D (cath-D) are involved in the prognosis of breast cancer (BC) and promote the metastatic process. We investigated the relationship between these proteases and their prognostic significance according to the ER status. Results: Quantitative levels of uPA and PA I-1 were higher in ER-patients (p < 0.001) whereas no difference was observed for cath-D levels in ER subsets (p = 0.96). In patients with a positive and highly positive ER status, a high cath-D level was associated with a poorer prognosis. Patients in the highly positive ER group experienced poorer survival in the group with a high PA I-1 level compared to the group with a low PA I-1 level. In ER+ patients, cath-D (p = 0.02) and the tumor size (p = 0.03) were independent factors for OS. Methods: uPA, PA I-1 and cath-D levels were prospectively measured in tumor from 316 patients with primary BC. The distribution and relationship between these proteases and ER subsets were analyzed as well as the prognostic significance. Conclusion: The prognostic significance of proteases is modulated by the ER status. Cath-D and PA I-1 could identify a high-risk group with an adverse outcome in ER+ patients. © 2011 Landes Bioscience. Source